These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29534926)

  • 1. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
    Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
    Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
    Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
    Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold.
    Hu J; Han Y; Wang J; Liu Y; Zhao Y; Liu Y; Gong P
    Bioorg Med Chem; 2018 May; 26(8):1810-1822. PubMed ID: 29486953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation.
    Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
    Chen L; Chi F; Wang T; Wang N; Li W; Liu K; Shu X; Ma X; Xu Y
    Bioorg Med Chem; 2018 Dec; 26(23-24):6087-6095. PubMed ID: 30471829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural modifications on indole and pyrimidine rings of osimertinib lead to high selectivity towards L858R/T790M double mutant enzyme and potent antitumor activity.
    Liu Q; Luo Y; Li Z; Chen C; Fang L
    Bioorg Med Chem; 2021 Apr; 36():116094. PubMed ID: 33667898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
    Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
    Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
    Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
    Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC.
    Chen L; Zhang Y; Tian L; Wang C; Deng T; Zheng X; Wang T; Li Z; Tang Z; Meng Q; Sun H; Li L; Ma X; Xu Y
    Eur J Med Chem; 2021 Nov; 223():113626. PubMed ID: 34218082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
    Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
    Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel pyrazole based Urea/Thiourea derivatives as multiple targeting VEGFR-2, EGFR
    Fadaly WAA; Nemr MTM; Kahk NM
    Bioorg Chem; 2024 Jun; 147():107403. PubMed ID: 38691909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
    Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
    Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
    Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X
    Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
    Zhao L; Fan T; Shi Z; Ding C; Zhang C; Yuan Z; Sun Q; Tan C; Chu B; Jiang Y
    Eur J Med Chem; 2021 Mar; 213():113173. PubMed ID: 33493830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.